ClinicalTrials.gov
ClinicalTrials.gov Menu

ivWatch Model 400: Device Validation for Infiltrated Tissues

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02123745
Recruitment Status : Completed
First Posted : April 28, 2014
Results First Posted : June 27, 2014
Last Update Posted : June 27, 2014
Sponsor:
Information provided by (Responsible Party):
ivWatch, LLC

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Diagnostic
Condition: Infiltration of Peripheral IV Therapy
Intervention: Device: The ivWatch Model 400

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Infiltrated Tissue

The ivWatch Model 400 monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.

The ivWatch Model 400: The ivWatch Model 400 monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.


Participant Flow:   Overall Study
    Infiltrated Tissue
STARTED   71 
COMPLETED   71 
NOT COMPLETED   0 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Infiltrated Tissue

The ivWatch Model 400 monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.

The ivWatch Model 400: The ivWatch Model 400 monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.


Baseline Measures
   Infiltrated Tissue 
Overall Participants Analyzed 
[Units: Participants]
 71 
Age 
[Units: Years]
Mean (Standard Deviation)
 38.2  (13.2) 
Age 
[Units: Participants]
 
<=18 years   1 
Between 18 and 65 years   69 
>=65 years   1 
Gender 
[Units: Participants]
 
Female   43 
Male   28 
Region of Enrollment 
[Units: Participants]
 
United States   71 
Body Mass Index 
[Units: Kg/m^2]
Mean (Standard Deviation)
 28.2  (6.61) 
Skin Pigmentation [1] 
[Units: Units on a scale]
Mean (Standard Deviation)
 1.704  (0.885) 
[1] Skin pigmentation was scored from 1 to 3 where 1 represents light skin pigmentation, 2 represents medium skin pigmentation, and 3 represents dark skin pigmentation.


  Outcome Measures

1.  Primary:   Red Notification Sensitivity to Infiltrated Tissues   [ Time Frame: After each participant has been infiltrated, an expected average of 1 hour ]

2.  Secondary:   Yellow Notification Sensitivity to Infiltrated Tissues   [ Time Frame: After each participant has been infiltrated, an expected average of 1 hour ]

3.  Secondary:   Infiltrated Volume When Red Notification Issued   [ Time Frame: After each participant has been infiltrated, an expected average of 1 hour ]

4.  Secondary:   Infiltrated Volume When Yellow Notification Issued   [ Time Frame: After each participant has been infiltrated, an expected average of 1 hour ]

5.  Secondary:   Significant Skin Irritation or Disruption to Skin Integrity   [ Time Frame: After each participant has been infiltrated, an expected average of 1 hour ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Garret T. Bonnema
Organization: ivWatch, LLC
phone: 1.855.489.2824 ext 7018
e-mail: garret.bonnema@ivwatch.com



Responsible Party: ivWatch, LLC
ClinicalTrials.gov Identifier: NCT02123745     History of Changes
Other Study ID Numbers: IVW400CS-06
First Submitted: April 22, 2014
First Posted: April 28, 2014
Results First Submitted: April 28, 2014
Results First Posted: June 27, 2014
Last Update Posted: June 27, 2014